Ribavirin treatment for chronic hepatitis C (Q50590272)

16 March 2018

title

Ribavirin treatment for chronic hepatitis C (English)

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)91707-2

25 October 2022

1 reference

1 reference

4

O Weiland

1 reference

16 March 2018

O. Reichard

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1673493

25 October 2022

J. Andersson

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1673493

25 October 2022

R. Schvarcz

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1673493

25 October 2022

language of work or name

English

0 references

publication date

1 May 1991

1 reference

16 March 2018

4 May 1991

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1673493

full work available at URL

25 October 2022

https://api.elsevier.com/content/article/PII:0140673691917072?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)91707-2

https://api.elsevier.com/content/article/PII:0140673691917072?httpAccept=text/plain

25 October 2022

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)91707-2

25 October 2022

1 reference

16 March 2018

volume

337

1 reference

16 March 2018

page(s)

1058-1061

1 reference

16 March 2018

issue

8749

1 reference

16 March 2018

Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome

cites work

1

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)91707-2

An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis

25 October 2022

2

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)91707-2

Non-A, non-B hepatitis after open-heart surgery in Stockholm: declining incidence after introduction of restrictions for blood donations due to the human immunodeficiency virus

25 October 2022

3

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)91707-2

Anti-hepatitis C antibodies and non-A, non-B post-transfusion hepatitis in The Netherlands

25 October 2022

4

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)91707-2

Long-term follow-up of chronic post-transfusion non-A, non-B hepatitis: clinical and histological outcome

25 October 2022

5

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)91707-2

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

25 October 2022

6

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)91707-2

Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

25 October 2022

7

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)91707-2

Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide

25 October 2022

8

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)91707-2

Molecular mechanisms of action of ribavirin

25 October 2022

9

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)91707-2

A phase 1 study of ribavirin in human immunodeficiency virus-infected patients

25 October 2022

12

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)91707-2

Evaluation of ribavirin in the treatment of acute hepatitis.

25 October 2022

13

1 reference

https://api.crossref.org/works/10.1016/0140-6736(91)91707-2

25 October 2022

Identifiers

1 reference

16 March 2018

1 reference

16 March 2018